Live
- VIP Treatment: Exclusive Benefits for High Rollers in Online Casino
- LS polls: Union Minister Bhagwanth Khuba, Dingaleshwara seer, Priyanka Jarkiholi file nominations in K'taka
- Amid show of strength, Congress’ Praniti Shinde files nomination from Solapur
- Tamil Nadu Police gives clean report to Isha Foundation in missing volunteers case
- Home Minister Amit Shah to address public meeting in Goa on April 24
- Gurgaon Open: M Dharma fires 67 for two-shot lead on penultimate day
- Sharad Pawar made many attempts to finish Shiv Sena, claims Maha minister
- Former England opener Raman Subba Row dies aged 92
- IPL 2024: Impact player rule is affecting the progress of half all-rounders, says Zaheer Khan
- ‘Teppa samudram’ review: Entertains with twists and turns
Plasma therapy not beneficial: ICMR Study
Plasma therapy not beneficial: ICMR Study
Use of convalescent plasma therapy in Coronavirus-infected patients does not help in reducing mortality or progression to severe COVID-19, a multi-centric study funded by the Indian Council of Medical Research (ICMR) has found
New Delhi: Use of convalescent plasma therapy in Coronavirus-infected patients does not help in reducing mortality or progression to severe COVID-19, a multi-centric study funded by the Indian Council of Medical Research (ICMR) has found.
The 'open-label parallel-arm phase II multicentre randomized controlled trial' (PLACID Trial) was conducted across 39 public and private hospitals across India between April 22 to July 14 to investigate the effectiveness of convalescent plasma (CP) for the treatment of COVID-19, it said.
The convalescent plasma (CP) therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those antibodies into an active coronavirus patient to help kickstart the immune system to fight the infection.
A total of 464 participants (moderately ill COVID-19 patients admitted to hospitals) were enrolled for the study, which has not yet been peer-reviewed and has appeared on medRxiv, a preprint server.
The National Task Force for COVID-19, a committee formed by the ICMR to respond to the pandemic, has reviewed and approved this study, it said.
